Research Progress on Point-of-Care Testing Technology for Mycoplasma Pneumonia
International Journal of General Medicine · 2026-03 · Volume 19 · 1-11
DOI: 10.2147/ijgm.s584824 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of General Medicine, 2026-03. Verfasst von Zimeng Guo und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Changchun University of Chinese Medicine, Changchun, People's Republic of China. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Mycoplasma pneumoniae (MP) is a significant respiratory pathogen in children, often causing refractory and severe pneumonia. Sensitive, rapid, and portable diagnostic tools are crucial for guiding clinical management. Although traditional methods like culture, ELISA, and PCR are widely used, they suffer from drawbacks such as lengthy turnaround times, complex procedures, or reliance on laboratory equipment. Consequently, Point-of-care testing (POCT) technologies, valued for their speed, portability, and ease of use, have emerged as a key research focus for MP diagnosis. This review systematically summarizes advancements in POCT platforms, covering: (1) immunological methods; (2) molecular biology methods; and (3) biosensor technologies. Their sensitivity, specificity, and clinical performance are comparatively analyzed. Colloidal gold immunochromatography delivers results within 15 minutes but exhibits limited sensitivity. Molecular methods like LAMP and CRISPR-coupled systems achieve single-copy detection limits via isothermal amplification and gene editing, with processing times under 1 hour. Biosensors enable high-sensitivity automated detection through integrated signal amplification and microfluidics. Despite these advantages, POCT development faces challenges including cost-sensitivity tradeoffs, standardization barriers, and sample matrix interference. Future directions encompass multi-modal detection, AI-assisted interpretation, multiplex pathogen screening, and dynamic drug resistance gene monitoring. These innovations will expand POCT device deployment in primary care and home settings. This will ultimately improve effectiveness in controlling respiratory infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, Changchun University of Chinese Medicine, Changchun, People's Republic of China.
- Publicity Section, Jilin Province Beef Cattle Industry Promotion Center, Changchun, People's Republic of China.
- Department of Pharmacy, The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, People's Republic of China.
- Innovation Practice Center, Changchun University of Chinese Medicine Innovation Practice Center, Changchun, People's Republic of China.
- Preventive Treatment Center, First Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People's Republic of China.
Zitieren
APA
Guo, Z., Hu, R., Wang, J., Zhou, M., Zhu, K., & Xu, Y. (2026). Research Progress on Point-of-Care Testing Technology for Mycoplasma Pneumonia. International Journal of General Medicine, Volume 19, 1-11. https://doi.org/10.2147/ijgm.s584824
Vancouver
Guo Z, Hu R, Wang J, Zhou M, Zhu K, Xu Y. Research Progress on Point-of-Care Testing Technology for Mycoplasma Pneumonia. International Journal of General Medicine. 2026;Volume 19:1-11. doi:10.2147/ijgm.s584824
BibTeX
@article{Guo2026,
author = {Guo, Zimeng and Hu, Ruige and Wang, Jun and Zhou, Mo and Zhu, Kai and Xu, Yunlong},
title = {Research Progress on Point-of-Care Testing Technology for Mycoplasma Pneumonia},
journal = {International Journal of General Medicine},
year = {2026},
volume = {Volume 19},
pages = {1--11},
doi = {10.2147/ijgm.s584824}
}
EUVIMED